Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Ascendis Pharma A/S Stock Price (Quote) NASDAQ:ASND
$140.74 ( -2.68% ) Monday, 25th Oct 2021
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $140.23 | $172.65 | Monday, 25th Oct 2021 ASND stock ended at $140.74. This is 2.68% less than the trading day before Friday, 22nd Oct 2021. During the day the stock fluctuated 3.46% from a day low at $140.23 to a day high of $145.08. |
| 90 days | $109.36 | $178.71 | |
| 52 weeks | $109.36 | $183.98 |
Historical Ascendis Pharma A/S prices
| Date | Open | High | Low | Close | Volume |
| 2021-10-25 | $144.38 | $145.08 | $140.23 | $140.74 | 378 968 |
| 2021-10-22 | $145.78 | $147.13 | $142.25 | $144.61 | 132 894 |
| 2021-10-21 | $144.04 | $151.91 | $142.17 | $145.62 | 638 517 |
| 2021-10-20 | $151.87 | $153.04 | $143.76 | $145.00 | 216 513 |
| 2021-10-19 | $155.32 | $158.05 | $152.16 | $153.49 | 262 599 |
| 2021-10-18 | $160.32 | $160.91 | $154.56 | $155.32 | 110 865 |
| 2021-10-15 | $161.36 | $162.14 | $155.13 | $159.99 | 329 955 |
| 2021-10-14 | $164.79 | $168.20 | $159.73 | $160.00 | 203 407 |
| 2021-10-13 | $168.23 | $171.64 | $163.16 | $164.00 | 177 242 |
| 2021-10-12 | $170.33 | $172.65 | $166.61 | $168.74 | 74 240 |
| 2021-10-11 | $169.27 | $171.48 | $165.76 | $169.66 | 107 492 |
| 2021-10-08 | $167.90 | $171.20 | $167.23 | $169.27 | 105 348 |
| 2021-10-07 | $162.66 | $167.83 | $160.40 | $167.25 | 101 425 |
| 2021-10-06 | $159.45 | $163.88 | $157.65 | $162.20 | 96 506 |
| 2021-10-05 | $162.49 | $163.86 | $159.58 | $159.61 | 82 509 |
| 2021-10-04 | $161.42 | $162.60 | $159.55 | $162.14 | 106 164 |
| 2021-10-01 | $159.50 | $163.54 | $157.02 | $162.25 | 220 252 |
| 2021-09-30 | $159.22 | $160.51 | $157.53 | $159.39 | 270 099 |
| 2021-09-29 | $161.43 | $162.29 | $155.48 | $157.00 | 95 627 |
| 2021-09-28 | $162.73 | $164.39 | $156.81 | $159.71 | 82 708 |
| 2021-09-27 | $164.40 | $167.50 | $163.02 | $163.41 | 116 019 |
| 2021-09-24 | $167.70 | $167.76 | $163.14 | $164.00 | 144 290 |
| 2021-09-23 | $158.48 | $169.84 | $156.98 | $168.30 | 256 607 |
| 2021-09-22 | $158.45 | $160.17 | $156.89 | $157.72 | 80 433 |
| 2021-09-21 | $158.24 | $160.95 | $156.06 | $158.45 | 72 311 |
| 2021-09-20 | $158.23 | $162.26 | $155.67 | $157.61 | 85 336 |
| 2021-09-17 | $158.97 | $163.21 | $158.20 | $161.51 | 295 266 |
| 2021-09-16 | $157.32 | $159.42 | $154.43 | $159.22 | 118 129 |
| 2021-09-15 | $153.56 | $157.33 | $152.00 | $157.32 | 142 375 |
| 2021-09-14 | $156.00 | $159.51 | $152.99 | $153.54 | 268 671 |
| 2021-09-13 | $156.29 | $160.22 | $152.25 | $157.40 | 99 482 |
| 2021-09-10 | $158.46 | $159.94 | $153.67 | $154.44 | 266 533 |
| 2021-09-09 | $159.09 | $162.46 | $157.20 | $158.46 | 132 311 |
| 2021-09-08 | $161.10 | $165.66 | $158.60 | $161.00 | 120 160 |
| 2021-09-07 | $164.27 | $167.51 | $161.06 | $164.11 | 252 629 |
| 2021-09-03 | $178.71 | $178.71 | $165.61 | $167.00 | 427 465 |
| 2021-09-02 | $169.59 | $177.84 | $167.50 | $176.92 | 620 238 |
| 2021-09-01 | $155.66 | $166.45 | $154.00 | $165.72 | 506 227 |
| 2021-08-31 | $154.28 | $158.30 | $154.28 | $156.73 | 227 090 |
| 2021-08-30 | $159.65 | $159.65 | $150.56 | $154.28 | 267 325 |
| 2021-08-27 | $151.00 | $157.49 | $150.45 | $154.76 | 419 295 |
| 2021-08-26 | $150.57 | $158.78 | $146.09 | $149.70 | 2 228 445 |
| 2021-08-25 | $121.90 | $124.40 | $119.62 | $123.67 | 205 912 |
| 2021-08-24 | $122.79 | $122.79 | $119.57 | $121.75 | 250 544 |
| 2021-08-23 | $120.71 | $122.71 | $120.50 | $122.00 | 228 331 |
| 2021-08-20 | $119.21 | $122.54 | $119.21 | $120.45 | 159 027 |
| 2021-08-19 | $118.39 | $120.16 | $117.04 | $119.08 | 147 643 |
| 2021-08-18 | $121.63 | $121.92 | $119.01 | $119.56 | 145 656 |
| 2021-08-17 | $115.87 | $121.90 | $115.19 | $121.34 | 230 954 |
| 2021-08-16 | $121.00 | $121.12 | $115.51 | $116.23 | 195 814 |
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in children and adults to treat growth hormone deficiency (GHD) and other indications; and TransCon Treprostinil that has completed Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening d... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 95.000+ Happy Subscribers
Don't miss out on the runners!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
